Pulse Journal Club Trending Explore Questions Researchers

Download the App

Join discussions, follow papers, and never miss your next session.

© Synapse Social LLC, 2026Privacy Policy

Home Explore Journal Club Trending

⌘+K

Impact of ibrutinib on inflammation in a mouse model of Graves’ orbitopathy | Synapse

August 30, 2024Open Access

Impact of ibrutinib on inflammation in a mouse model of Graves’ orbitopathy

Key Points

Key points are not available for this paper at this time.

Abstract

Bruton's tyrosine kinase (BTK) and interleukin (IL)-2 Inducible T-cell Kinase (ITK) inhibitors have anti-inflammatory properties. We investigated the therapeutic effect of ibrutinib, an orally bioavailable BTK/ITK inhibitor, in a mouse model of Graves' orbitopathy (GO).

Read Full Paperexternally

Mark Helpful

Bookmark

Relay

View Full Paper

Mark Helpful

Bookmark

Relay

View Full Paper

Cite This Study

Kim et al. (Fri,) studied this question.

synapsesocial.com/papers/68e5a4ccb6db64358753f153 https://doi.org/https://doi.org/10.3389/fendo.2024.1420024

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Treatment of Active Corticosteroid-Resistant Graves’ Orbitopathy2014 · 195 citations
2The Pathogenesis of Lupus Nephritis2014 · 76 citations
3Current Insights into Animal Models of Graves' Disease and Orbitopathy2013 · 43 citations
4Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton's tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis2019 · 28 citations
5Steroid-Resistant Graves’ Orbitopathy Treated with Tocilizumab in Real-World Clinical Practice: A 9-Year Single-Center Experience2021 · 65 citations